title: Modified platelet responses to thrombin. Evidence for two types of receptors or coupling mechanisms.
abstract: The normally quick response of platelets to alpha-thrombin is delayed under two conditions. After pretreatment of platelets with chymotrypsin or certain other proteases, aggregation and secretion induced by alpha-thrombin begins after a delay of 30 s or more compared to less than 5 s for control platelets, and control platelets are activated by gamma-thrombin with a similar delay (Tam, S. W., Fenton, J. W., II, and Detwiler, T. C. (1980) J. Biol. Chem. 255, 6626-6632). Under these conditions, thrombin-induced inhibition of adenylate cyclase was blocked. The impaired regulation of adenylate cyclase and delayed secretion had in common: (i) partial correction with high concentrations of thrombin; (ii) similar thrombin dose-response relationships; (iii) similar concentration dependence for chymotrypsin during pretreatment; and (iv) specificity for thrombin. Other parameters of thrombin-induced platelet activation were also analyzed under these conditions. Thrombin-induced hydrolysis of arachidonyl esters and synthesis of prostanoids were similar to regulation of adenylate cyclase; they were blocked, with partial correction at high concentrations of thrombin. In contrast, thrombin-induced synthesis of phosphatidic acid and phosphorylation of a 20- and a 40-kDa protein were similar to secretion; they occurred after a delay but to a normal extent. The thrombin-induced increase in cytosolic calcium ion activity was slightly slower in chymotrypsin-treated platelets or in response to gamma-thrombin, but it was complete prior to initiation of the delayed responses. It is concluded that platelets have at least two types of thrombin receptors or coupling mechanisms, one of which is sensitive to chymotrypsin, unresponsive to gamma-thrombin, and coupled to inhibition of adenylate cyclase and activation of prostanoid synthesis.
mesh_terms: D000067956:Adenylyl Cyclase Inhibitors; D001792:Blood Platelets / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D002918:Chymotrypsin / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D008970:Molecular Weight; D010712:Phosphatidic Acids / Q000378:metabolism; D010766:Phosphorylation; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000096:biosynthesis; D011956:Receptors, Cell Surface / Q000378:metabolism; D018179:Receptors, Thrombin; D013917:Thrombin / Q000494:pharmacology*
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D010712:Phosphatidic Acids; D011453:Prostaglandins; D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; D000242:Cyclic AMP; D002918:Chymotrypsin; D013917:Thrombin; D019204:GTP-Binding Proteins; D002118:Calcium